Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Familial non-medullary thyroid cancer (FNMTC) constitutes 3–9% of all thyroid cancer cases and is divided into syndromic and non-syndromic FNMTC.
After receiving a diagnosis of papillary thyroid cancer, intuitively, the thought has been that surgery is the next step. While this was the standard in the past, we now know that in specific situations immediate surgery may not be necessary.
Thyroid Journal Program Thyroid®, Clinical Thyroidology®, and VideoEndocrinology™ Latest Impact Factor: 5.309 Special Collection: Virtual Review…